All articles

Making the full impact of a rare disease asset clear

Performing a risk assessment of the policy landscape and market trends to inform commercialization plan

Developing a pre-launch roadmap ahead of launch for CGT rare disease asset

Women's health
2026 midterm results create new opportunities in women’s health policy

Market and industry dynamics
White paper: Payment chain vs. supply chain–how they differ and why it matters

Drug pricing and affordability
OBBBA and Medicare negotiation eligibility: Considerations for manufacturers

Rare disease
What does payer-informed evidence generation for rare disease therapies look like?

Drug pricing and affordability
FFS vs. MA utilization will impact relative net prices in negotiation

Drug pricing and affordability
Differences in Part B and D pricing for IPAY 2028 drugs

Market and industry dynamics
How do Medicare Advantage and Medicare FFS utilization patterns differ?
